8-K: Theriva Biologics Sets 2025 Annual Meeting for August 29, Announces Revised Shareholder Proposal Deadlines

Theriva Biologics, Inc. has announced August 29, 2025, as the date for its 2025 Annual General Meeting of Shareholders, leading to revised deadlines for stockholder proposals and director nominations.

Summary

• Theriva Biologics, Inc. (the "Company") has scheduled its 2025 Annual General Meeting of Shareholders (the "2025 Annual Meeting") for August 29, 2025.
• The record date for determining stockholders entitled to vote at the 2025 Annual Meeting is the close of business on July 8, 2025.
• Due to the 2025 Annual Meeting being more than 30 days prior to the anniversary of the 2024 annual meeting, previously disclosed deadlines for stockholder proposals under Rule 14a-8 are no longer applicable.
• The new deadline for stockholder proposals submitted pursuant to Rule 14a-8 for inclusion in the Company's proxy statement is July 5, 2025.
• The deadline for other stockholder proposals or director nominations not seeking inclusion in proxy materials (outside Rule 14a-8) is also July 5, 2025.
• Stockholders intending to solicit proxies for director nominees other than the Company's nominees must provide notice as required by Rule 14a-19 by July 5, 2025.
• An adjournment or postponement of the 2025 Annual Meeting will not create new or extend existing deadlines for stockholder proposals.

Sentiment

Score: 5

Explanation: The document is purely administrative, announcing a meeting date and revised deadlines. It contains no information that would inherently be positive or negative for the company's financial performance or strategic direction.

Future Outlook

The Company will set forth the time and location of the 2025 Annual Meeting in its definitive proxy statement, which will be filed with the SEC.

Industry Context

This filing is a standard administrative update for a publicly traded company, announcing its annual shareholder meeting and associated deadlines, which is a routine corporate governance practice across all industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the announcement of the annual meeting date, the record date for voting eligibility, and the revised deadlines for submitting proposals and director nominations. This requires them to be aware of and adhere to the new, earlier deadlines if they wish to participate in these processes.

Next Steps

• The Company will file its definitive proxy statement for the 2025 Annual Meeting with the SEC, which will include the time and location of the meeting.
• Stockholders wishing to submit proposals under Rule 14a-8 must do so by July 5, 2025.
• Stockholders wishing to submit director nominations or other proposals not under Rule 14a-8 must do so by July 5, 2025.
• Stockholders intending to solicit proxies for director nominees must provide Rule 14a-19 notice by July 5, 2025.

Key Dates

Keywords

Annual General Meeting, Shareholder Meeting, Proxy Statement, Stockholder Proposals, Director Nominations, SEC Filing, Form 8-K, Corporate Governance, Theriva Biologics